Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to ensure equal insurance coverage for cancer drugs regardless of treatment type.
The problem
Cancer patients may face unequal insurance coverage depending on whether their treatment is oral medication, infusion, or other drug types, creating access disparities.
The proposal
Requires insurance plans to cover cancer drugs equally without discrimination based on drug delivery method or administration route.
The impact
Cancer patients, insurance companies, pharmaceutical manufacturers, and healthcare providers face changes in coverage requirements and potential cost shifts.
Ensures all cancer patients can access prescribed medications without discrimination based on how the drug is delivered. Removes barriers that prevent some patients from receiving their doctor's recommended treatment.
Eliminates surprise cost differences between similar cancer drugs. Patients won't pay more simply because their medication comes in pill form versus injection form.
Allows doctors to choose treatments based on medical effectiveness rather than insurance coverage limitations. May accelerate development of new cancer drug delivery methods.
When patients access prescribed medications without delay or substitution, health outcomes typically improve. Prevents treatment delays caused by insurance coverage disputes.
Requiring equal coverage for all drug types may increase insurance premiums overall. Insurers may pass these costs to employers and individuals through higher monthly payments.
Insurance companies currently use different coverage levels to manage costs and encourage generic alternatives. This bill may limit their ability to keep premiums affordable.
Different insurance plans operate differently across states. Enforcing uniform coverage requirements could be complex and create compliance difficulties for insurers.
Insurance companies might require patients to try cheaper drugs first before approving expensive ones. The requirement doesn't prevent this 'step therapy' approach that can delay treatment.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.